TMC114

DRUG5 trials

Sponsors

Tibotec Pharmaceuticals, Ireland

Conditions

HIVHIV InfectionHIV InfectionsHIV-1

Phase 2

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

CompletedNCT00081588

Tibotec Pharmaceuticals, IrelandHIV Infection

Start: 2003-11-30End: 2008-12-31Updated: 2014-06-20

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

CompletedNCT00355524

Tibotec Pharmaceuticals, IrelandHIV-1, HIV Infections

Start: 2006-06-30End: 2011-03-31Updated: 2013-07-08

TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains

CompletedNCT00964327

Tibotec Pharmaceuticals, IrelandHIV Infections

Start: 2001-08-31End: 2003-10-31Updated: 2011-05-19

A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials

CompletedNCT02187107

Tibotec Pharmaceuticals, IrelandHIV

Start: 2005-01-31End: 2009-03-31Updated: 2014-08-25

Phase 3

TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options

CompletedNCT00115050

Tibotec Pharmaceuticals, IrelandHIV Infections

Start: 2005-06-30End: 2007-06-30Updated: 2011-06-10

Related Papers

Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged<b>≥</b>3 to <12 Years

CPT Pharmacometrics & Systems Pharmacology2015-06-1912 citations